Ivana Magovcevic - Ipsen SA Executive Vice President Chief Business Officer
| IPSEY Stock | USD 29.36 1.47 5.28% |
President
Dr. Ivana MagovcevicLiebisch, Ph.D. J.D. serves as Executive Vice President, Chief Business Officer of Ipsen SA since March 13, 2018. She is in charge of Business Development, External Innovation and Strategic Alliances. She joins Ipsen from Axcella Health Inc., where she served as Executive Vice President, Chief Strategy and Corporationrationrate Development Officer. Prior to joining Axcella, Ivana was Senior Vice President and Head of Global Business Development at Teva Pharmaceutical Industries Ltd, where she led and executed multiple business development transactions ranging from licensing to acquisition of drug candidates, commercial products and companies for the global specialty drug business. She previously worked at Dyax Corporationration in management roles of increasing scope and responsibility, including Executive Vice President and Chief Operating Officer. She began her biopharma career at Transkaryotic Therapies, Inc, where she was Director of Intellectual Property and Patent Counsel. Ivana serves as a member of the Board of Directors of Applied Genetic Technologies Corporation, is also a member of the Board of Directors for Alivio Therapeutics, and was most recently appointed to the Board of Directors of Aeglea BioTherapeutics. Ivana is Trustee of Suffolk University, and an overseer of the Boston Ballet, Boston Museum of Science and Beth Israel Deaconess Medical Center. Ivana holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology law from Suffolk University Law School. She graduated from Wheaton College with a B.A. in Biology and Chemistry. In 2008, Ivana was the winner of the Women Entrepreneurs in Science and Technology Leadership Award. since 2018.
| Age | 49 |
| Tenure | 6 years |
| Phone | 33 1 58 33 50 00 |
| Web | https://www.ipsen.com |
Ipsen SA Management Efficiency
The company has return on total asset (ROA) of 0.1026 % which means that it generated a profit of $0.1026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1944 %, meaning that it generated $0.1944 on every $100 dollars invested by stockholders. Ipsen SA's management efficiency ratios could be used to measure how well Ipsen SA manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 562.8 M in total debt with debt to equity ratio (D/E) of 0.38, which is about average as compared to similar companies. Ipsen SA ADR has a current ratio of 1.84, which is within standard range for the sector. Debt can assist Ipsen SA until it has trouble settling it off, either with new capital or with free cash flow. So, Ipsen SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ipsen SA ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ipsen to invest in growth at high rates of return. When we think about Ipsen SA's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Myriam Theeuwes | Durect | N/A | |
| Cartikeya Reddy | Dr Reddys Laboratories | 46 | |
| Samiran Das | Dr Reddys Laboratories | 56 | |
| Lawrence Wennogle | Intracellular Th | 65 | |
| Lawrence Hineline | Intracellular Th | 61 | |
| Scott Braunstein | Pacira Pharmaceuticals | 52 | |
| Peter Boyd | Aquestive Therapeutics | 58 | |
| Ronald Janish | Perrigo Company PLC | 58 | |
| K Rao | Dr Reddys Laboratories | 53 | |
| Sharon Kochan | Perrigo Company PLC | 52 | |
| Todd Kingma | Perrigo Company PLC | 61 | |
| Steven Passik | Collegium Pharmaceutical | N/A | |
| John Wesolowski | Perrigo Company PLC | 49 | |
| Douglas Boothe | Perrigo Company PLC | 51 | |
| Theresa Wood | Aquestive Therapeutics | 54 | |
| Suresh Durgam | Intracellular Th | N/A | |
| Richard Bartram | Esperion Therapeutics | 36 | |
| Marc Coucke | Perrigo Company PLC | 49 | |
| Parker Javid | Lifecore Biomedical | 55 | |
| Thomas Farrington | Perrigo Company PLC | 67 | |
| Yael Brenner | Kamada | 51 | |
Management Performance
Ipsen SA ADR Leadership Team
Elected by the shareholders, the Ipsen SA's board of directors comprises two types of representatives: Ipsen SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ipsen. The board's role is to monitor Ipsen SA's management team and ensure that shareholders' interests are well served. Ipsen SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ipsen SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Herve Couffin, Independent Director | ||
| Helene AuriolPotier, Director | ||
| Carol Xueref, Independent Director | ||
| Richard Paulson, Executive Vice President and CEO of Ipsen North America | ||
| Yan Moore, Senior Vice President Head of Oncology Therapeutics Area | ||
| James Levine, President | ||
| Margaret Liu, Independent Director | ||
| Claude Bertrand, Chief Scientific Officer and Executive VP of RandD | ||
| Stephane Bessette, Executive Vice President of Human Resources | ||
| Christel Bories, Deputy CEO | ||
| Christophe Verot, Director | ||
| Regis Mulot, Chief Human Resource Officer, Executive Vice President | ||
| Jean Fabre, Executive Vice President - Primary Care Business Unit, Member of the Executive Committee | ||
| David Meek, CEO | ||
| Alexander McEwan, Vice President and Head of Radiopharmaceuticals | ||
| Etienne Blois, Vice President Latin America, Spain and Portugal | ||
| Ivana MagovcevicLiebisch, Executive Vice President Chief Business Officer | ||
| Philippe Bonhomme, Director - Representative of Mayroy SA | ||
| Heather White, Vice President Global Internal Audit | ||
| Martha Crawford, Independent Director | ||
| Harout Semerjian, Executive Vice President & President Specialty Care International & Global Franchises | ||
| Anne Beaufour, Director | ||
| Christopher Masterson, Senior Vice President Quality | ||
| Benoit Hennion, Executive Vice President - Primary Care Business Unit, Member of the Executive Committee | ||
| Antoine Flochel, Vice Chairman of the Board | ||
| Marc Garidel, Chairman, CEO and Chairman of Strategic Committee | ||
| Henri Beaufour, Director | ||
| Gwenan White, Ex Affairs | ||
| Francois Garnier, Executive Vice President General Counsel, Member of the Executive Committee | ||
| Ivana Magovcevic, Executive Vice President Chief Business Officer | ||
| Dominique Bery, Executive Vice President Strategu & Transformation | ||
| Alexandre LeBeaut, Executive Vice President Research & Development, Chief Scientific Officer | ||
| Pierre Boulud, Executive Vice President - Specialty Care Commercial Operations, Member of the Executive Committee | ||
| Aidan Murphy, Executive Vice-President Technical Operations | ||
| David Loew, CEO MD | ||
| Craig Marks, VicePres Relations | ||
| Pierre Martinet, Independent Director | ||
| Yan MD, VP Area | ||
| Jonathan Barnsley, Executive Vice-President Technical Operations, Member of the Executive Committee | ||
| Dominique Brard, Executive Vice President - Human Resources and Member of the Executive Committee | ||
| FrancoisMaurice Garnier, Executive Vice President General Counsel | ||
| Cynthia Schwalm, the United States General Manager | ||
| Philippe RobertGorsse, Executive Vice President - Specialty Care Franchises, Member of the Executive Committee | ||
| Michele Ollier, Independent Director | ||
| Carol Stuckley, Independent Director | ||
| Christophe Jean, Executive Vice President - Group Strategy and Business Development, Member of the Executive Committee | ||
| Aymeric Chatelier, Executive VP of Fin. and Member of Chairman's Committee | ||
| Didier Veron, Senior Vice President Public Affairs and Corporate Communication | ||
| Eugenia Litz, Vice President of Investor Relations | ||
| Dominique Laymand, Senior Vice President Chief Ethics and Compliance Officer | ||
| Stephan Gagne, Head Office |
Ipsen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ipsen SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 8.28 B | |||
| Shares Outstanding | 330.56 M | |||
| Price To Earning | 14.23 X | |||
| Price To Book | 2.73 X | |||
| Price To Sales | 2.72 X | |||
| Revenue | 3.16 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ipsen SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ipsen SA's short interest history, or implied volatility extrapolated from Ipsen SA options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ipsen SA ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Ipsen SA ADR information on this page should be used as a complementary analysis to other Ipsen SA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Ipsen Pink Sheet analysis
When running Ipsen SA's price analysis, check to measure Ipsen SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ipsen SA is operating at the current time. Most of Ipsen SA's value examination focuses on studying past and present price action to predict the probability of Ipsen SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ipsen SA's price. Additionally, you may evaluate how the addition of Ipsen SA to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |